Table 1 Characteristics of the study patients.
|  |  | Total (n = 53) |
|---|---|---|
Sex, n | Male | 36 (67.9%) |
| Â | Female | 17 (32.1%) |
Age, median (range), years |  | 68 (40–77) |
Location, n | Upper | 4 (7.5%) |
| Â | Middle | 35 (66.0%) |
| Â | Lower | 14 (26.4%) |
Size, median (range), mm |  | 30 (4–122) |
Macroscopic type, n | 0–I | 2 (3.8%) |
|  | 0–IIa | 6 (11.3%) |
|  | 0–IIb | 10 (18.8%) |
|  | 0–IIc | 32 (60.3%) |
|  | 0–III | 3 (5.6%) |
Magnifying endoscopic findings* | ||
Type of IPCL, n | B1 | 36 (67.9%) |
| Â | B2 | 5 (9.4%) |
| Â | B3 | 11 (20.8%) |
AVA, n | None | 12 (46.2%) |
| Â | Small | 13 (24.5%) |
| Â | Middle | 20 (37.7%) |
| Â | Large | 7 (13.2%) |
FDG PET/CT and Parameters | ||
SUV max, average (SD) | Â | 2.3 (3.2) |
MTV, average (SD) | Â | 1.0 (2.1) |
TLG, average (SD) | Â | 4.0 (9.7) |
Treatment | ||
ESD | Â | 27 (50.9%) |
Surgical resection | Â | 26 (49.1%) |
Pathological diagnosis | Â | Â |
Invasion depth, n | EP | 3 (5.6%) |
| Â | LPM | 15 (28.3%) |
| Â | MM | 11 (20.7%) |
| Â | SM1 | 7 (13.2%) |
| Â | SM2 | 7 (13.2%) |
| Â | SM3 | 10 (18.8%) |
Lymphatic involvement | Positive cases, n | 12 (22.6%) |
Venous involvement | Positive cases, n | 7 (13.2%) |
Lymph nodes metastasis | Positive cases, n | 4 (7.6%) |
Distant metastasis | Positive cases, n | 0 (0.0%) |
